Relmada Therapeutics, Inc. RLMD Stock Appreciation Rights Compensation
Stock Appreciation Rights Compensation at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlmd:StockAppreciationRightsCompensation.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s stock appreciation rights compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s stock appreciation rights compensation?
- Relmada Therapeutics, Inc. (RLMD) reported stock appreciation rights compensation of $2.68M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s stock appreciation rights compensation changed year-over-year?
- Relmada Therapeutics, Inc.'s stock appreciation rights compensation increased by 88038.6% year-over-year, from $3.04K to $2.68M.
- What does stock appreciation rights compensation mean?
- The expense associated with stock appreciation rights (SARs), which provide employees with the right to receive cash or stock equal to the increase in the company's share price. This reflects the cost of performance-based incentives tied directly to market valuation growth.